Loading stock data…
FENC
$6.54+0.05 (+0.77%)
Market ClosedLast close May 1
Fennec Pharmaceuticals Inc.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Fennec Pharmaceuticals Inc. in the Healthcare sector is trading at $6.54. The stock is currently 34% below its 52-week high of $9.92, remaining 18.0% below its 200-day moving average. Technical signals show neutral RSI of 61 and bullish MACD crossover, explaining why FENC maintains its current current market pressure. The Whystock Score of 35/100 signals elevated caution as indicators diverge.
Ecosystem Influences
Neutral momentum (RSI 61) — price action in range
Long-term trend bearish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current Price$6.54
Potential Upside
5%
Whystock Fair Value$6.87
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Mean target$15.17+131.9%
Range$13.00 – $18.00
Fundamentals
Fennec Pharmaceuticals Inc. operates as a commercial stage biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of cisplatin-induced ototoxicity pedia...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$230.29M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
Defensive asset. Lower volatility than the S&P 500.
0.93
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
-27.46%
Volume
Today's trading volume
133,570
Recent News
Wedbush Refines Fennec Pharmaceuticals Estimates Ahead of Q1 Earnings
Wedbush is refining its its 2026 estimates for Fennec Pharmaceuticals (FRX.TO) ahead of the company
Companies Like Fennec Pharmaceuticals (NASDAQ:FENC) Can Afford To Invest In Growth
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Fennec Pharmaceuticals Inc. Q4 2025 Earnings Call Summary
Moby summary of Fennec Pharmaceuticals Inc.'s Q4 2025 earnings call
Fennec Pharmaceuticals Inc (FENC) Q4 2025 Earnings Call Highlights: Record Sales and Strategic ...
Fennec Pharmaceuticals Inc (FENC) reports a 75% increase in Q4 net product sales, debt-free status, and strategic market expansions amid rising expenses.
Adherex Technologies Q4 Earnings Call Highlights
Fennec Pharmaceuticals reported record commercial growth for PEDMARK during its fourth quarter and full year 2025 earnings call, highlighting expanding adoption in both new and existing accounts, improved patient support metrics, and steps to broaden clinical evidence supporting the drug’s use beyon